Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Carcinoma, Merkel Cell 2

Interventions

pembrolizumab 9avelumab 8Nivolumab 6Ipilimumab 4Radiotherapy 3durvalumab 2cemiplimab 2atezolizumab 2aldesleukin 2Specimen Handling 2Radiation 2Magnetic Resonance Spectroscopy 2Interferon-beta 2Cyclophosphamide 2Biopsy 2Bevacizumab 2tremelimumab 1sargramostim 1sapanisertib 1regorafenib 1prednylidene 1poly ICLC 1navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1lutetium Lu 177 dotatate 1interferon gamma-1b 1epacadostat 1efineptakin alfa 1deltacortene 1decitabine and cedazuridine drug combination 1bempegaldesleukin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Merkel Cell × Interferon-beta × Clear all
NCT02584829 2022-03-22

Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma

Fred Hutchinson Cancer Center

Phase 1/2 Terminated
8 enrolled 16 charts
Dermatologic

Carcinoma, Merkel Cell

NCT01758458 2017-04-19

Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma

Fred Hutchinson Cancer Center

Phase 1/2 Terminated
4 enrolled
Dermatologic

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡